Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $14.33

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned an average rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $14.33.

ZURA has been the subject of several analyst reports. Guggenheim restated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital cut their price target on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. HC Wainwright restated a “buy” rating on shares of Zura Bio in a research note on Thursday, April 3rd. Finally, Oppenheimer reduced their price target on shares of Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Friday, May 9th.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in shares of Zura Bio during the fourth quarter valued at $371,000. American Century Companies Inc. acquired a new position in shares of Zura Bio in the 4th quarter valued at about $27,000. Prudential Financial Inc. acquired a new position in shares of Zura Bio in the 4th quarter valued at about $28,000. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after purchasing an additional 2,611,532 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Zura Bio by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock worth $2,389,000 after purchasing an additional 42,801 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Stock Performance

Zura Bio stock opened at $1.30 on Friday. Zura Bio has a 52 week low of $0.97 and a 52 week high of $5.07. The stock has a fifty day moving average price of $1.15 and a 200 day moving average price of $1.39. The firm has a market capitalization of $88.89 million, a P/E ratio of -1.86 and a beta of -0.10.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). As a group, equities analysts predict that Zura Bio will post -0.65 EPS for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.